Hepatic Artery Ligation and Cytotoxic Infusion in Treatment of Liver Metastases

Gulesserian, H. P.

doi:10.1001/archsurg.1972.04180080132022

Cited by 36 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to reports from Hong Kong and Japan, the median survival for these patients ranges from 3.5 weeks [19] to 1.6 months [20], comparable to the figure of 58 days for patients in the control group of this study. Many palliative surgical procedures have been devised and these uncontrolled studies all claim good results [3][4][5][6][7][8][9][10][11]. These procedures include varying degrees of interruption of the hepatic arterial supply to the liver, with or without cytotoxic drug infusion.…”

Section: Discussionmentioning

confidence: 99%

“…Balasegaram [5] and Almersjo et al [6] showed that hepatic dearterialization could result in good symptomatic palliation coupled with prolonged survival in selected patients. Infusion of chemotherapeutic agents via the intraportal or intra-arterial route had also been advocated to deal with the residual tumor after interruption of the hepatic arterial inflow [7][8][9][10]. Ariel and Pack reported in 1964 that external irradiation might be of value for the disease, but the small series of 10 patients showed inconclusive results [11].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of unresectable hepatocellular carcinoma : Results of a randomized controlled trial

et al. 1986

View full text Add to dashboard Cite

Most patients with hepatocellular carcinoma present late with unresectable disease and, to date, an effective and safe palliative treatment has not been found. From December 1971, to December 1981, a randomized controlled trial was conducted to evaluate the following treatments against a control group receiving only symptomatic therapy (group I): hepatic dearterialization (group II), hepatic artery ligation and cannulation for infusion of chemotherapeutic agents (group III), hepatic artery ligation and portal vein cannulation for chemotherapeutic agents infusion (group IV), and external irradiation (group V). Response to various treatments was assessed with respect to symptomatic relief and duration of survival. A total of 166 patients with histologically confirmed tumor confined to the liver were studied. All patients had similar preoperative general status and biochemical findings. Patients in group IV had the best symptomatic improvement; 58.6% responded to some degree. Hepatic artery ligation intraportal infusion (group IV) offered significantly longer survival than infusion via the intra-arterial route (group III) (p = 0.023). However, when compared with the control group, the survival times in the 4 treatment groups were not significantly different. Hepatic dearterialization (group H) had the highest 7-day mortality rate, 33.3%. The results of this trial suggested that none of the modalities of treatment studied offered patients with unresectable hepatocellular carcinoma any better survival and symptomatic palliation than did symptomatic treatment alone.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Treatment of unresectable hepatocellular carcinoma : Results of a randomized controlled trial

et al. 1986

View full text Add to dashboard Cite

show abstract

“…Gulesserian, Lawton, and Condon [38] treated six patients who had liver metastasis with hepatic artery ligation and infusion of 5FU to the distal hepatic arterial system. They pointed out that all patients lived much longer than the expected median survival of patients with untreated hepatic metastasis (8.5 vs 2.5 months).…”

Section: Hepatic Artery Ligation and Infusion Chemotherapymentioning

confidence: 99%

Nonsystemic treatment of metastatic tumors of the liver—a review

Lee

1978

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy. Nonsystemic treatment of metastatic tumors of the liver include surgical resection; infusion of chemotherapeutic agent(s), either via hepatic artery or portal vein; ligation of hepatic artery; radiotherapy; and other more investigative approaches (isolation perfusion, cryosurgery, liver transplantation, etc). The relative applicability, results, and limitations of each of these therapeutic modalities are reviewed.

show abstract

“…Dearterialization has been combined with local infusion of oncolytic drugs either into the portal vein (Murray-Lyon et al, \91Q\ Aimers jo et al, 1976) or into the hepatic artery distal to the ligature (Guelessarian et al, 1972). An alternative method for tempory interruption of hepatic blood flow has been devised in rats by Rothman et al (1976), using a new type of degradable microspheres.…”

Section: Introductionmentioning

confidence: 99%

Controlled Blocking of Hepatic Artery Flow with Enzymatically Degradable Microspheres Combined with Oncolytic Drugs

Aronsen¹,

Hellekant²,

Holmberg³

et al. 1979

Eur Surg Res

View full text Add to dashboard Cite

A new method for intermittent hepatic arterial flow arrest has been used in combination with intraarterial 5-fluorouracil (5-Fu) for the treatment of secondary liver neoplasms in 12 patients. Polysaccharide microspheres with a half-life of 1 h were infused together with 5-Fu via a percutaneously introduced catheter into the hepatic artery. There were no significant side effects to the treatment. Clinical effects and overall survival were comparable to those of hepatic artery ligation.

show abstract

Hepatic Artery Ligation and Cytotoxic Infusion in Treatment of Liver Metastases

Cited by 36 publications

References 0 publications

Treatment of unresectable hepatocellular carcinoma : Results of a randomized controlled trial

Treatment of unresectable hepatocellular carcinoma : Results of a randomized controlled trial

Nonsystemic treatment of metastatic tumors of the liver—a review

Controlled Blocking of Hepatic Artery Flow with Enzymatically Degradable Microspheres Combined with Oncolytic Drugs

Contact Info

Product

Resources

About